PIVOT-006 Phase 3, randomized open-label monotherapy study evaluating cretostimogene grenadenorepvec for the treatment of Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (NMIBC)

REVIEW UroToday

Breaking Paradigms: BOND-003's Cretostimogene Monotherapy for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Mark Tyson

BOND-003 Phase 3 Results: Revolutionizing Bladder Cancer Treatment with Intravesical Cretostimogene Grenadenorepvec Monotherapy for High-Risk BCG-Unresponsive NMIBC - Mark Tyson

Physician-Scientist Review Articles

State of the Evidence Review Articles